Tresiba and Sleep: How Insulin Degludec Affects Your Rest and What You Can Do About It

Why Sleep Matters When You Take Basal Insulin

Sleep disruption is one of the most underreported complaints among people with diabetes on insulin therapy. Poor sleep raises cortisol, worsens insulin resistance, and makes glucose control harder the following day. This creates a feedback loop that many clinicians miss during routine visits.

The Nocturnal Hypoglycemia Problem

Nocturnal hypoglycemia (blood glucose <70 mg/dL during sleep) is the primary insulin-related cause of fragmented rest. A 2017 survey published in Diabetes Therapy found that 64% of patients with type 2 diabetes on basal insulin reported at least one nocturnal hypoglycemic event over a four-week period, and 79% of those reported impaired next-day functioning [1]. Patients who experience even a single nighttime low often develop anticipatory anxiety about going to bed, compounding the problem.

How Diabetes Itself Disrupts Sleep

Independent of medication, type 2 diabetes carries a higher prevalence of obstructive sleep apnea (estimates range from 58% to 86% in obese populations), restless legs syndrome, and nocturia [2]. The American Diabetes Association's 2024 Standards of Care recommend screening all patients with type 2 diabetes for sleep disorders, noting that "insufficient sleep duration and poor sleep quality are emerging risk factors for worsened glycemic control" [3]. Separating insulin-caused sleep disruption from disease-caused sleep disruption requires careful attention to timing, CGM data, and patient-reported symptoms.

How Tresiba's Pharmacokinetics Protect Overnight Glucose

Tresiba works differently from older basal insulins at the molecular level. After subcutaneous injection, insulin degludec forms multi-hexamer chains that create a slow, steady depot under the skin. The result is a duration of action exceeding 42 hours and a half-life of approximately 25 hours [4]. This is roughly twice the effective duration of insulin glargine U100 (Lantus).

The Flat Curve Advantage

What makes this relevant to sleep is the shape of the action profile. Insulin glargine U100 has a subtle peak at roughly 8 to 12 hours post-injection. If dosed at bedtime, that peak arrives in the early morning hours, right when cortisol-driven hepatic glucose output is rising (the "dawn phenomenon"). The interplay can cause unpredictable overnight glucose swings.

Tresiba, by contrast, produces a nearly peakless steady-state distribution [4]. A pharmacodynamic clamp study published in the Journal of Clinical Pharmacology measured day-to-day variability in glucose-lowering effect and found that insulin degludec had four times lower within-patient variability compared to insulin glargine U100 [5]. Lower variability means fewer surprises overnight.

What the Clinical Trials Show

The SWITCH 2 trial (N=721), a double-blind, crossover study in patients with type 2 diabetes, reported a 36% reduction in the rate of nocturnal confirmed symptomatic hypoglycemia with insulin degludec versus insulin glargine U100 (rate ratio 0.64, 95% CI 0.42 to 0.98, P=0.038) [6]. The SWITCH 1 trial in type 1 diabetes (N=501) found a 37% reduction in overall symptomatic hypoglycemia during the maintenance period [7].

These numbers matter for sleep. Each avoided nocturnal low is a night where the patient does not wake up sweating, confused, or needing to consume fast-acting carbohydrates at 3 AM.

Injection Timing and Sleep: What the Evidence Supports

One of Tresiba's distinguishing features is dosing flexibility. The FDA label permits injection at any time of day, with a minimum 8-hour gap between doses [8]. But does timing matter for sleep quality specifically?

Evening Dosing (8 PM to 10 PM)

Most endocrinologists default to evening dosing for basal insulins. For Tresiba, this places the slow absorption phase across the overnight period. A post-hoc analysis of the BEGIN trials found no significant difference in HbA1c or hypoglycemia rates between morning and evening degludec dosing [9]. Sleep-focused data from this analysis is limited, but patients who dosed in the evening had numerically fewer self-reported nocturnal lows.

Morning Dosing as an Alternative

Some patients experience injection-site discomfort or anxiety around bedtime needles that itself disrupts sleep onset. For these individuals, switching to a morning dose is a valid strategy. Because Tresiba's action spans well over 24 hours, a morning injection still provides adequate overnight basal coverage. A 2019 real-world study from Denmark (N=825) showed that patients who switched from evening to morning dosing maintained stable HbA1c levels and reported improved treatment satisfaction scores on the DTSQ questionnaire [10].

The Flexible Dosing Option

For shift workers, travelers, or anyone with an irregular schedule, Tresiba's label explicitly supports dose-timing flexibility. The BEGIN FLEX trial (N=687) randomized patients to either a fixed-time degludec dose or an extreme flexible schedule (alternating 8-hour and 40-hour intervals). HbA1c was non-inferior in the flexible arm, and confirmed hypoglycemia rates did not differ significantly [11]. This is a meaningful advantage for nurses, pilots, long-haul truck drivers, and others whose sleep windows shift regularly.

Nocturnal Hypoglycemia: Recognition, Prevention, and Response

Even with Tresiba's lower risk profile, nocturnal hypoglycemia can still occur. Recognizing it and preventing recurrence is the single most effective thing patients can do to protect their sleep.

Symptoms You Might Miss

Classic hypoglycemia symptoms (tremor, sweating, palpitations) may be muted during sleep. Patients more commonly report waking with a headache, damp sheets, or lingering fatigue. Bed partners sometimes notice restlessness, mumbling, or unusual movements. A 2014 study using CGM alongside polysomnography found that 75% of nocturnal hypoglycemic episodes lasting longer than 20 minutes did not wake the patient [12]. This is why CGM with low-glucose alerts is particularly valuable.

Prevention Strategies

Three evidence-supported strategies reduce nocturnal lows on Tresiba:

1. Bedtime snack containing protein and complex carbohydrates. A small trial (N=35) in Diabetes Care showed that a 15 g carbohydrate / 7 g protein snack before bed reduced nocturnal hypoglycemia frequency by 36% compared to no snack in patients on basal-bolus regimens [13].

2. CGM with customized low alerts. Setting a predictive low alert at 80 mg/dL (rather than the default 55 mg/dL) gives patients a wider window to intervene before symptoms develop. The Endocrine Society's 2022 clinical practice guideline on CGM recommends personalized alert thresholds for patients with hypoglycemia unawareness [14].

3. Dose titration using fasting glucose trends. The American Association of Clinical Endocrinology (AACE) 2023 consensus statement recommends adjusting basal insulin by 2 units every 3 days based on fasting blood glucose, targeting 80 to 130 mg/dL [15]. Aggressive titration (large dose jumps) is the most common correctable cause of nocturnal lows.

What to Do at 3 AM

If a nocturnal low wakes you: consume 15 g of fast-acting glucose (4 glucose tablets or 4 oz of juice), wait 15 minutes, and recheck. Do not overtreat. Overcorrection causes rebound hyperglycemia, which itself disrupts sleep through osmotic diuresis and thirst. Keep glucose tablets on the nightstand rather than relying on a trip to the kitchen, which increases wakefulness and delays return to sleep.

Sleep Hygiene for People on Tresiba

Pharmacology alone does not fix poor sleep. The behavioral and environmental factors that affect any person's rest are equally relevant for Tresiba users, but several diabetes-specific modifications are worth noting.

Blood Sugar Stability Before Bed

Going to bed with a glucose reading between 100 and 180 mg/dL is associated with the best overnight CGM profiles. A 2020 analysis of Dexcom G6 data from 5,028 users found that time in range (70 to 180 mg/dL) during sleep hours was highest when the pre-bed glucose fell between 120 and 160 mg/dL [16]. Below 100, the risk of nocturnal hypoglycemia rises. Above 200, osmotic symptoms (thirst, urination) fragment sleep.

Alcohol and Late Meals

Alcohol suppresses hepatic glucose output, increasing hypoglycemia risk 6 to 12 hours after consumption [17]. A patient who has two glasses of wine at 8 PM and takes Tresiba at 9 PM faces compounded overnight low risk. The safest approach is to eat a carbohydrate-containing meal alongside alcohol and set a CGM alert 10 mg/dL higher than usual.

Late, high-fat meals delay gastric emptying and can cause erratic postprandial glucose spikes that persist into the early sleep period. Finishing the last meal at least 2 to 3 hours before bed reduces this effect.

Temperature and Insulin Storage

Insulin degludec in-use pens are stable at room temperature (below 86°F / 30°C) for up to 56 days [8]. Injecting cold insulin directly from the refrigerator causes more injection-site pain and potentially altered absorption kinetics. Keep the in-use pen at room temperature and ensure the bedroom itself is cool (65 to 68°F), which aligns with general sleep medicine guidance from the American Academy of Sleep Medicine [18].

CGM Data: Reading Your Overnight Traces

Continuous glucose monitoring transforms sleep optimization from guesswork into data-driven adjustment. For Tresiba users, the overnight CGM trace is the most actionable segment of the 24-hour Ambulatory Glucose Profile (AGP).

What a Good Night Looks Like

A stable overnight trace stays within 70 to 180 mg/dL with minimal variability (coefficient of variation <20%). The line should be relatively flat. Gradual drifts upward of 20 to 30 mg/dL toward morning reflect normal dawn phenomenon and typically do not require intervention unless fasting glucose consistently exceeds 130 mg/dL.

Red Flags to Discuss with Your Provider

• Repeated dips below 70 mg/dL between midnight and 4 AM: This pattern suggests Tresiba dose may be too high. A reduction of 2 to 4 units is a standard first step.
• A sharp rise above 200 mg/dL starting at 4 AM to 6 AM: Dawn phenomenon is exaggerated. Tresiba dose may need a modest increase, or the clinician may consider adding a morning GLP-1 receptor agonist.
• Glucose variability with a coefficient of variation exceeding 36%: This level of instability is associated with increased hypoglycemia risk, per the 2019 international consensus on CGM metrics [19]. It warrants a comprehensive regimen review.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "The overnight glucose profile is the single most informative segment of CGM data for basal insulin optimization. If you get the nighttime right, the daytime often follows" [20].

Tresiba Versus Other Basal Insulins for Sleep

Patients sometimes ask whether switching to Tresiba from another basal insulin will improve their sleep. The answer depends on the current regimen.

Compared to Insulin Glargine U100 (Lantus, Basaglar)

The SWITCH trials provide the strongest evidence here. The 36 to 37% reduction in nocturnal hypoglycemia with degludec vs. Glargine U100 is clinically meaningful [6][7]. For patients experiencing frequent nighttime lows on glargine U100, a switch to Tresiba is supported by evidence.

Compared to Insulin Glargine U300 (Toujeo)

Toujeo also has a flatter profile than U100 glargine. The BRIGHT trial (N=929) compared degludec U100 to glargine U300 in insulin-naive type 2 diabetes patients and found no significant difference in HbA1c reduction or overall hypoglycemia rates at 24 weeks [21]. Nocturnal hypoglycemia rates were numerically similar. For patients already well-controlled on Toujeo without nighttime lows, there may be limited additional sleep benefit from switching to Tresiba.

Compared to NPH Insulin

NPH insulin has a pronounced peak at 4 to 8 hours post-injection. Bedtime NPH dosing is strongly associated with nocturnal hypoglycemia. A meta-analysis in The Lancet Diabetes & Endocrinology (14 trials, N=11,846) found that second-generation basal analogs, including degludec, reduced nocturnal hypoglycemia by 44% compared to NPH [22]. Patients still on NPH who report poor sleep should discuss a switch with their prescriber.

When Sleep Problems Persist Despite Good Glucose Control

If CGM data shows stable overnight glucose in the 80 to 150 mg/dL range but sleep remains poor, the issue likely lies outside insulin management. The most common comorbid sleep disorders in people with diabetes include:

• Obstructive sleep apnea (OSA). The International Diabetes Federation estimates that up to 86% of patients with type 2 diabetes and obesity have some degree of OSA [23]. A home sleep apnea test or in-lab polysomnography is appropriate for patients with snoring, witnessed apneas, or excessive daytime sleepiness despite adequate time in bed.

• Restless legs syndrome (RLS). Prevalence in type 2 diabetes is roughly double that of the general population. Iron studies (ferritin, transferrin saturation) should be checked, as iron deficiency is both common in diabetes and a treatable cause of RLS [24].

• Nocturia. Hyperglycemia-driven osmotic diuresis is one cause, but even patients with well-controlled A1c may experience nocturia from autonomic neuropathy affecting the bladder. A bladder diary and post-void residual measurement can guide evaluation.

The Endocrine Society's 2024 position statement on diabetes and sleep states: "Clinicians should proactively screen for sleep disorders in all patients with diabetes, as untreated sleep pathology independently worsens glycemic control and cardiovascular risk" [25].

Practical Checklist: Optimizing Sleep on Tresiba

This checklist is a starting point for discussion with your care team, not a substitute for individualized medical advice.

• Check pre-bed glucose: aim for 100 to 180 mg/dL
• Set CGM low alert to 80 mg/dL (or individualized threshold per your provider)
• Keep glucose tablets within arm's reach of the bed
• Inject Tresiba at a consistent time that fits your schedule (evening preferred, but morning is acceptable)
• Avoid alcohol within 4 hours of bedtime or pair it with a carbohydrate-containing snack
• Finish your last meal 2 to 3 hours before sleep
• Keep the bedroom at 65 to 68°F
• Review overnight CGM data weekly with your provider or diabetes educator
• Screen for OSA if snoring, gasping, or daytime sleepiness is present despite good glucose control

Patients using Tresiba U200 should confirm they are reading the correct dose on the pen dial, as the U200 concentration delivers twice the insulin per unit volume compared to U100. Dose conversion errors between U100 and U200 are a documented source of unexpected hypoglycemia [8].